CELERA - Geht´s jetzt los ???? - 500 Beiträge pro Seite

[WWW.MONEY2EARN.DE]

CELERA in Amerika +27,37%

[/url]

Wie geht´s jetzt weiter?


http://www.money2earn.de/

[WWW.MONEY2EARN.DE]

Celera Genomics: Maus-DNA nahezu entschlüsselt

Celera Genomics macht große Fortschritte beim Erforschen der menschlichen DNA. Erst vor kurzem berichtete die Biotechfirma, daß man den Druchbruch noch in diesem Jahr schaffen wolle. Die Aktie stürmte daraufhin nach oben, denn wer die DNA zuerst entschlüsselt, darf auch die Patente beanspruchen.
Heute gab man bekannt, die DNA der Maus fast fertig entschlüsselt zu haben: 1,15 Milliarden Basispaare wurden schon entcodiert. Dieses neue Wissen will man jetzt auch beim menschlichen Code einsetzen.

QUELLE: www.finance-online.de


http://www.money2earn.de/" target="_blank" rel="nofollow ugc noopener">http://www.money2earn.de/

[Pitcairn]

Celera Genomics steht anscheinend kurz davor, das menschliche Erbgut vollständig zu entschlüsseln. Möglicherweise geschieht dies sogar schon in den nächsten Tagen:

Saturday, 3 June, 2000, 07:45 GMT 08:45 UK

Genome puzzle near to solution


The genome will promote a deeper understanding of human life

A team of scientists racing to become the first to work out the detailed composition of human DNA says it is close to achieving its goal.
The team - from the American company Celera Genomics - says it is on course to beat a rival, publicly funded effort.

Its leader, Doctor Craig Venter, told Radio 4`s Today programme he believed his researchers would finish their work to map the human genome this month.



Venter: Leading the race

The task, which involves decoding the entire three billion letters of human DNA, will be hailed as a monumental scientific achievement.

The first scientists to sequence the human genome, described as the "blueprint of humanity", will earn themselves a place in the history books.

The wealth of information gleaned from the landmark discovery will enable the creation of new medicines and a deeper knowledge of how human life evolves.

If Dr Venter is to scoop first place in the scientific race he needs to complete his research in the next few days.

A rival publicly-funded bid to unravel the human genome say they are on course to complete the project by mid-June.

The publicly-funded Human Genome Project scientists form part of a 12-year, $3bn programme, of which $500m is being spent on the human genome.

Dr Venter first caused uproar in 1998 by saying he would decode the entire genome in just three years at a 10th of the cost of the public project.

He could be on course to fulfill this promise, as he says he will make an announcement in the next few days.

The publicly-funded group will make its findings freely available on the Internet, whereas Celera Genomics plans to sell the information.

Dr Venter dismissed suggestions that selling the sequenced code was immoral and pointed out that medicines such as insulin and cancer treatments were already based on genetic research.

He said of the critics: "I hope these people don`t have anybody in their family who is using insulin to treat diabetes, that they are not using key drugs to helping cancer chemotherapy patients.

"I think it is fantastic that the pharmaceutical industry and the biotech industry are coming up with new treatments.

"If you want to live in the dark ages where there is no treatment for diseases then we should eliminate all these processes."

Dramatic discovery

Piecing together all parts of the human genome jigsaw was an unthinkable task 15 years ago, making its imminent discovery all the more dramatic.

The 2m long string of DNA found in nearly every human cell contains the instructions for every physical aspect of the human body, from the pattern of fine capillaries in the lungs to the unique speckled pattern of the iris.

Access to such fundamental information promises a new era of medicine and long-term hope for sufferers of a myriad of illnesses.

In the far future, it may be possible to prevent genetic diseases from being inherited by cutting them out of the gene pool altogether, in what is called germline engineering.

At the nearer end of the time scale, genetic tests are allowing people to choose suitable therapies and lifestyles to beat disease.

Quelle: http://news.bbc.co.uk/hi/english/in_depth/sci_tech/2000/huma…

[Pitcairn]

Hier ist ein weiterer aktueller Artikel zu Celera Genomics:

http://www.wired.com/news/technology/0,1282,36654,00.html

[Pitcairn]

Celera hat heute in USA bei 92 $ geschlossen (+ 34,3 %)!

[stockstudi]

Celeras Kursanstieg beruht auf einem Radiointerview seitens Firmengründers Craig Venter,welches in etwa besagt ,daß die Genkarte des Menschen zu 100 % entschlüsselt sei und man bis Ende Juni in der Lage ist die wichtigsten Gensequenzen seiner Funktion nach zuzuordnen.
1. Stimmt das,dann ist das Unternehmen in der Lage Patente anzumelden,die nach derzeitiger Rechtslage in den Staaten erteilt werden,insofern eine unabhängige Kommission Celeras Ergebnisse bestätigt. Dieses Szenario würde der Lizenz zum Geld drucken gleich kommen und der Kurs wird gewaltig steigen(wie gesagt: in mehreren postings habe ich darauf hingewiesen,das Celera im Erfolgsfalle das Potenzial zum Mikrosoft der Biotechnik hat.Das Unternehmen hat in seinen zeitlichen Vorgaben im Bezug auf seine geplanten Forschungserfolge bisher nicht enttäuscht.)
2. Venter hat in seinem Ehrgeiz übertrieben und seine Aussagen entsprechen nicht,bzw. noch nicht der Wahrheit,dann wird der Kurs wieder purzeln.

Meine Meinung zu diesem Unternehmen: Wer Geld übrig hat sollte kaufen und zwischenzeitliche Verluste von 60-70 % mit einkalkulieren.Im Falle des nicht Erfolges vieleicht noch mehr. Im Falle des Erfolges hat der jetzt investierte Investor die Möglichkeit an einem der sagenhaftesten Börsenrallys der letzten Jahre teil zuhaben.

Fazit: Nur für Zocker und nichts für die sichere Rendite,aber eine irre Chance.

p.s: Ist gibt kaum einen Ort auf dieser Erde,der es im Bezug auf Risiko und Weitsicht der Börse gleichtut: Der risikoreiche Anleger kann fürstlich belohnt,aber auch bettelarm werden.

[Sugar1]

Klär mich bitte mal jemand auf: Da ist scheinbar nachbörslicher Handel in Celera.

in New York ist der letzte Kurs vor 10 Minuten mit 97 Dollar !!!!!!!!!!!!!!! gestellt worden.

Consors weisst per kurz vor 12 Uhr 92 Dollar aus.

Cool

Sugar1

[Sugar1]

Klär mich bitte mal jemand auf: Da ist scheinbar nachbörslicher Handel in Celera.

in New York ist der letzte Kurs vor 10 Minuten mit 97 Dollar !!!!!!!!!!!!!!! gestellt worden.

Consors weisst per kurz vor 12 Uhr 92 Dollar aus.

Cool

Sugar1

[stockstudi]

Genau das ist es. Falls Du den Wert schon längere Zeit beobachtest,dann fällt auf ,daß Celera nachbörslich gehandelt wird. 97$ entspricht einem Kursgewinn von über 40 %. Und das läßt mich mit einem Grinsen einschlafen,denn ich glaube an dieses Unternehmen und habe mir vorgenommen die Teile die nächsten 10 Jahre nicht anzupacken! entweder werde ich belohnt,oder ich bin mit dem Bewustsein auf die Schnute gefallen an einen Wert zu glauben der eine überdurchschnittliche Rendite versprochen hat.

[barri]

Heißt das mann mu? Celera jetzt noch schnell kaufen????
Zweite Frage das ist alles korrekt mit der menschlichen DNA wie Ihr es geschrieben habt.

Sorry wenn ich Frage ich bin Neu und habe diesen Wert bei mir noch nicht im Depot aber wenn Ihr mir das bestätigt dann kaufe ich gleich, weil dann ist Wachstum und jede Menge Kursgewinne Vorprogrammiert.

Mit freundlichen Grüßen


barri

[stadtursel]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[GUMASI]

Interessanter Motley-Fool-Artikel unter:
http://www.fool.com/portfolios/rulebreaker/2000/rulebreaker0…

[JeGo71]

Hoffen wir mal das Celera um 15:30Uhr an der Nasdaq die 97$ ausbauen kann. Hier in Frankfurt wurde der Kurs noch nicht richtig berücksichtigt -> 101 Euro währe da fair, denke ich!

[bucs]

...laßt Euch nur blenden, schaut Euch mal den Intraday-chart an, da hat jemand in den letzten Stunden ganz gewaltig gepusht, ich denke nicht, daß die die 100 $ überqueren, sondern vielmehr in die Region um 80-83 $ zurückfallen werden, deshalb ist der Makler in FFM auch vorsichtig.
Was natürlich nicht heißen soll, der Wert wäre nichts, im Gegenteil, ich bin auch überzeugt.

[Pitcairn]

Craig Venter, Präsident von Celera Genomics, hält heute um 9:10 Ortszeit auf einer Konferenz des National Institutes of Health eine Rede zum Thema "Genomes Completed by Whole Shotgun Sequencing:From Haemophilus Influenza to Drosophila to Human". Möglicherweise gibt er da die vollständige Entschlüsselung bekannt.

Quelle: http://www4.od.nih.gov/gmcrf/Program.htm

[stockstudi]

Celera gibts heute in Berlin ca.8% günstiger,als es die faire Taxierung des Kurses von gestern in Amerika darlegt!
Schlußkurs N.Y.: 105.25 $
Berlin 9.40Uhr : 103.00 Euro

Geht Biotech heute ,dann ist dies sehr günstig. Sollte der Markt heute einigermaßen stabil sein wird Celera outperformen!

[aktienfilter]

craig venter ist nicht gerade garant für seriösität, schon 1992 hat mit einer anderen firma immer wieder für überraschungen gesorgt, aber letztlich erfolglos geblieben. hier liegen aber nicht meine bedenken gegenüber celera. die universität cambridge kündigt ebenfalls die gen-entschlüsselung binnen kürzester zeit an, evtl in den nächsten 2 moanten. wichtiger: sie will die datenbank dann kostenfrei ins internet stellen! bitte überlegt mal, ob vor diesem hintergrund nicht die möglichkeit besteht, daß celera vergeblich geforscht hat? ich bin im mai in millennium, protein design labs und genentech eingestiegen, nachdem ich diese aktien und zusätzllich genome therapeutics ende februar verkauft hatte. jetzt werde ich noch neurosearch und phraming group hinzuaddieren.

[Pitcairn]

Wednesday, June 07, 2000


Markets Anticipate Celera’s Gene Mapping Progress

June 7, 2000

by Amy Tsao

A rumor that Celera (NYSE: CRA) has completed the arduous task of mapping the human genome sent genomic companies’ stocks sky high yesterday, but today some shares are giving back a portion of those recent gains.

According to the rumor, Celera, which had said it would announce its sequenced genome sometime this summer, has already finished the task. Publicly, the company has said only that it is nearing the finish line, and might beat the government-run initiative.

“The markets seem to be anticipating an announcement from Celera very soon about major progress on mapping the human genetic code,” said Kimberly Tanner, associate analyst with Medical Technology Stock Letter. “Sellers have all suddenly gotten out of the way.”

Yesterday, the biotech indexes outperformed a Nasdaq decline of 1.71%. The Nasdaq Biotechnology Index closed up 3.05% and the AMEX Biotechnology Index rose 4.01%.

Does the Celera rumor justify yesterday’s meteoric rise of recent IPO Genomics Solutions (NASDAQ: GNSL)? The stock, which was trading flat at 8 before Tuesday, soared 30% to 11 1/4.

Genomics Solutions’ stock was further propelled 30% to 14 5/8 Wednesday morning after the lead underwriter for its initial public offering, UBS Warburg, started coverage with a ‘strong buy’ rating.

Looking at the charts of some genomics stocks, upticks began last Friday with an overall market rally and an even stronger day for biotechs. Indeed, some stocks have gained as much as 40% in the last week.

Celera stock soared as high as 118 5/8 during yesterday’s session alone and finished the day up 19% at 105.25. The stock is up 44% since last Friday. Human Genome Sciences (NASDAQ: HGSI) is up 10% since Friday, after giving back some gains late in the day Tuesday and early today.

Small cap genomics stocks like Hyseq (NASDAQ: HYSQ) and Gene Logic (NASDAQ: GLGC) are up 20% and 23%, respectively, since Friday.

Now that the Celera rumor seems to have cooled down, biotech momentum has slowed. The Nasdaq Biotechnology Index was up just 0.01% and the AMEX Biotechnology Index was off 1.05%.

Though they are up over the last few trading sessions, Celera, Human Genome Sciences and Hyseq have all given back some of their recent gains today. Other genomics companies, Myriad Genetics (NASDAQ: MYGN) and Sequenom (NASDAQ: SQNM), are in the same boat.

So, what gives? Many analysts previously said that reaching the genome map milestone this summer has already been been factored into the sector’s stock prices.

But it appears many investors can’t forget the buzz surrounding genomics companies, which focus on technologies that will help make drugs based on genetic information. After all, these companies started the biotech rally that began last winter and lasted into the early days of March.

A summer slump is expected for stocks throughout biotechnology, but there is speculation that the sector could get a boost when either Celera or the publicly funded Human Genome Project announces that it has a completed genome map in hand.

“There definitely could be an updraft,” said Matt Kaplan, an analyst at Evolution Capital. “The question is, is it an updraft with staying power?”

Quelle: http://www.smallcapcenter.com/story.asp?storytype=sccnews&co…

Scheinen wohl ziemlich viele Kurzzeit-Zocker in den Wert eingestiegen zu sein. Celera aktuell in USA bei 96 $ (-8,8 %).

[WWW.MONEY2EARN.DE(gesperrt)]

Wednesday June 7, 3:27 pm Eastern Time
US Congress urged to outlaw genetic discrimination
By Maggie Fox, Health and Science Correspondent

WASHINGTON, June 7 (Reuters) - It will be impossible to keep details of people`s genes secret in the future, so Congress should pass laws to make sure such information is not abused, Craig Venter, founder of gene-mapping company Celera Genomics Inc. (NYSE:CRA - news), said on Wednesday.

``I argue that it is virtually impossible to achieve full medical privacy,`` Venter, whose company is working furiously to map and identify all the genes in the human genome, told a ``High-tech summit`` held by the Joint Economic Committee of the House of Representatives and Senate.

``Accepting this fact highlights our need for legislation prohibiting discrimination on the basis of genetic information. It is essential if the biotechnology revolution is to be realised.``

Scientists who are mapping the human genome hope they will eventually be able to identify the genes that make people susceptible to diseases ranging from cancer to Alzheimer`s. They also hope to be able to identify who responds well to which drugs, so that medicine can be tailored to individuals.

Already many genes associated with disease have been identified, including many cancer genes, a gene for Huntington`s, which is an inherited and incurable brain illness, and genes associated with haemophilia.

People have already expressed worries about being tested for such genes, saying they fear they will be denied health insurance and might lose jobs if it became known they were at risk of disease.

In February President Bill Clinton signed an executive order prohibiting the government from using genetic information in hiring or promotion decisions. And Congress is working on this, in the form of the Genetic Nondiscrimination in Health Insurance and Employment Act of 1999.

The legislation, introduced by Senate minority leader Tom Daschle, a South Dakota Democrat, and New York Democratic Representative Louise Slaughter, would extend federal genetic employment protections to the private sector.

``The biggest concern is genetic discrimination,`` Venter said.

``Because we differ subtly from one another, some people want to over-interpret this in terms of genetic determinism -- that you are what you are because of your genetic code,`` he added. ``It doesn`t quite work like that.``

Venter stressed that environment is at least as important as genetics. He pointed out if one identical twin has schizophrenia, a disease with a genetic component, the other twin has only a 50 percent chance of developing the illness, even though the two have exactly the same genes.

Venter said everybody has one gene or another that, if they are allowed to, could give insurance companies an excuse not to provide cover. ``Every one of us is uninsurable,`` he said.

He said people should not want their genetic make-up to remain secret, because there are benefits to knowing about it.

``Each one of us, when our genetic code is determined, and if I have my way every one of us will have our genetic code determined within the next 10 to 15 years, will be able to do tailored and preventive medicine,`` he said.

Referring to the prostate-specific antigen test used to find a protein over-produced by prostate cancer cells, Venter said: ``Hopefully, from this we will have a new blood test for cancer like the PSA test.``

Another fear is that people who wish to discriminate against various ethnic groups might try and use genetics as a weapon. ``We don`t want the genetic code to be used ... by people trying to justify their previous biases,`` Venter said.


http://WWW.MONEY2EARN.DE/(gesperrt)

[Pitcairn]

Hier ein aktueller Artikel, in dem Venter zu den Gerüchten um die bevorstehende Meldung der kompletten Entschlüsselung des menschlichen Erbguts Stellung nimmt:


Celera CEO Clears up Rumor

June 7, 2000
(Bridge News

Celera Genomics Group (NYSE: CRA) President J. Craig Venter said Wednesday that his company`s announcement of a complete draft of the human genome will come later this month. Speaking to reporters after a Capitol Hill hearing, Venter said Tuesday`s rumors of an announcement coming today were "completely made up."

Congress` Joint Economic Committee is sponsoring the High-Tech Summit, a hearing where prominent CEOs are testifying on trade and policy barriers they feel are hindering the growth of the new economy.

At the hearing, Venter told the committee that better-than-expected progress led Celera to announce in April that it had completed the sequencing phase of decoding the human genome.

"We expect to announce that we have assembled all the raw data into a properly ordered sequence with full-length genes within the month of June," Venter told the committee. "Later this year we will publish the human genome."

After the hearing, Venter told reporters that his company will likely make the official announcement on a Monday morning in June, before the market opens. It is also likely that the company would send out word of the Monday press conference the Friday before, after markets had closed.

"It will be a Monday in June," Venter said of the announcement.

Late Tuesday, rumors circulated on Wall Street that Celera was going to make the genome announcement Wednesday morning. Shares of Celera jumped $7, or 7.2%, Tuesday to close at $104 on the New York Stock Exchange.

Venter denied those reports today.

"That was completely made up by somebody in the British press," he said. "I don`t know where that came from."

During his testimony, Venter told the committee that the genome, when made available, will be a "very powerful" information tool that, among other things, could help individuals understand what illnesses they are genetically predisposed to so that action could be taken before disease sets in.

"It is about creating a world where disease is a rarity, and medicine is preventative," he said. "...Hopefully out of this we`ll have new blood tests for different types of cancer."

By Mark Tarallo, Bridge News

Quelle:
Congress` Joint Economic Committee is sponsoring the High-Tech Summit, a hearing where prominent CEOs are testifying on trade and policy barriers they feel are hindering the growth of the new economy.

At the hearing, Venter told the committee that better-than-expected progress led Celera to announce in April that it had completed the sequencing phase of decoding the human genome.

"We expect to announce that we have assembled all the raw data into a properly ordered sequence with full-length genes within the month of June," Venter told the committee. "Later this year we will publish the human genome."

After the hearing, Venter told reporters that his company will likely make the official announcement on a Monday morning in June, before the market opens. It is also likely that the company would send out word of the Monday press conference the Friday before, after markets had closed.

"It will be a Monday in June," Venter said of the announcement.

Late Tuesday, rumors circulated on Wall Street that Celera was going to make the genome announcement Wednesday morning. Shares of Celera jumped $7, or 7.2%, Tuesday to close at $104 on the New York Stock Exchange.

Venter denied those reports today.

"That was completely made up by somebody in the British press," he said. "I don`t know where that came from."

During his testimony, Venter told the committee that the genome, when made available, will be a "very powerful" information tool that, among other things, could help individuals understand what illnesses they are genetically predisposed to so that action could be taken before disease sets in.

"It is about creating a world where disease is a rarity, and medicine is preventative," he said. "...Hopefully out of this we`ll have new blood tests for different types of cancer."

By Mark Tarallo, Bridge News

Quelle: http://www.smallcapcenter.com/story.asp?storytype=sccnews&co…

Fazit: Die Meldung kommt noch im Juni, wann genau steht aber noch nicht fest." target="_blank" rel="nofollow ugc noopener">Friday, June 09, 2000


Celera CEO Clears up Rumor
June 7, 2000
(Bridge News)
Celera Genomics Group (NYSE: CRA) President J. Craig Venter said Wednesday that his company`s announcement of a complete draft of the human genome will come later this month. Speaking to reporters after a Capitol Hill hearing, Venter said Tuesday`s rumors of an announcement coming today were "completely made up."

Congress` Joint Economic Committee is sponsoring the High-Tech Summit, a hearing where prominent CEOs are testifying on trade and policy barriers they feel are hindering the growth of the new economy.

At the hearing, Venter told the committee that better-than-expected progress led Celera to announce in April that it had completed the sequencing phase of decoding the human genome.

"We expect to announce that we have assembled all the raw data into a properly ordered sequence with full-length genes within the month of June," Venter told the committee. "Later this year we will publish the human genome."

After the hearing, Venter told reporters that his company will likely make the official announcement on a Monday morning in June, before the market opens. It is also likely that the company would send out word of the Monday press conference the Friday before, after markets had closed.

"It will be a Monday in June," Venter said of the announcement.

Late Tuesday, rumors circulated on Wall Street that Celera was going to make the genome announcement Wednesday morning. Shares of Celera jumped $7, or 7.2%, Tuesday to close at $104 on the New York Stock Exchange.

Venter denied those reports today.

"That was completely made up by somebody in the British press," he said. "I don`t know where that came from."

During his testimony, Venter told the committee that the genome, when made available, will be a "very powerful" information tool that, among other things, could help individuals understand what illnesses they are genetically predisposed to so that action could be taken before disease sets in.

"It is about creating a world where disease is a rarity, and medicine is preventative," he said. "...Hopefully out of this we`ll have new blood tests for different types of cancer."

By Mark Tarallo, Bridge News

Quelle: http://www.smallcapcenter.com/story.asp?storytype=sccnews&co…

Fazit: Die Meldung kommt noch im Juni, wann genau steht aber noch nicht fest.

[GUMASI]

Ist CELERA vom Handel ausgesetzt, kriege keinen Kurs ?

[matthze]

Celera um 15.48 h bei 98.75 US$.

[matthze]

16.46 h Celera bei 110 Euro in Frankfurt. Geht´s jetzt los??

[matthze]

16.46 h Celera bei 110 Euro in Frankfurt. Geht´s jetzt los??

[GUMASI]

Danke, keine Ahnung warum yahoo und quote.com
1/2 Stunde keinen Kurs hatten.

[GUMASI]

Celera stellt sich gegen den Biotech-Trend,
ist auf jeden Fall gestern nicht gefallen.

Fazit: Es kann aufwärts gehen

[GUMASI]

CELERA schon wieder im PLUS gegen den Trend,
wegen Zusammenarbeit mit GERON.

-----------------
Friday June 23, 11:00 am Eastern Time
Forbes.com
Geron Gets Cloning Patents
By Matthew Herper


Could cloning save your liver? Geron hopes so.

On June 21, the United Kingdom granted two patents for technologies that were used in creating the cloned sheep Dolly in 1997. Geron (Nasdaq: GERN - news), a Menlo Park, Calif., biopharmaceutical company, bought an exclusive license to these patents as part of its $44.4 million acquisition of Roslin Bio-Med and most other patents that resulted from the Dolly experiment.

Dolly was the first clone, or copy, of an existing animal. Dolly and the donor sheep were genetically identical, like twins, except that the clone was much younger than the other. The public debate focused on the morality of cloning whole animals, and so it conjured up sci-fi images of a society in which everyone has identical faces, and cloned bodies are grown in vats.

Geron is hoping to use this technology not to copy whole animals, which has proved difficult and inefficient, but instead to create organs and cells for transplant. The liver is Geron`s first target in its plan to use cloning technologies, called nuclear transfer, to produce transplantable cells and organs from the patient`s own body. This is part of the company`s focus on what David Earp, Geron`s vice president of intellectual property, calls ``regenerative medicine.``

``Nuclear transfer is really about the ability to take an adult cell and basically reprogram it so that you can grow an embryo from it,`` Earp says.

The process involves making a cell forget its identity as one particular kind of cell in favor of becoming another kind. Skin cells can become heart cells or vice versa. After the change is made, the cell then reproduces, creating more of the new kind of cells. Geron is specifically interested in growing liver cells.

Scientists say the new liver cells could be injected into a diseased liver. Because these cells would essentially be clones made from the patient`s own cells, there would be no risk of the rejection problems typical with organ transplants, and therefore no need for the drugs that prevent the immune system from attacking a transplanted organ.

``We`re still a long way off,`` says Earp. But he says Geron has another way that the technology can make money for it in the meantime. As soon as they know how to make liver cells from embryonic stem cells, it can start selling them to drug companies. Such cells would provide a much more reliable method of testing drugs` poison content than currently exists.

Geron could certainly use a product. It has an impressive collection of patents and new technologies. But in 1999, it had revenue of $5.4 million and a net loss of $46.4 million. A recent partnership with genomics leader Celera (NYSE: CRA - news) could help, but eventually Geron`s technologies will have to start actually making money.

``The commercial viability of this is years down the road,`` says Steve Brozak, an analyst at Vanguard Capital. ``This is brave new world stuff. This is something that is significant in terms of building bridges to other things.``

Go to www.forbes.com to see all of our latest stories.

[GUMASI]

jetzt scheint´s ja wirklich loszugehen,
Celera überspringt locker die 100$-Marke.